A clinical-stage biotechnology company announced the progression of its development program for its lead drug candidate, ABX464, into phase 3 preparation for the treatment of moderate-to-severe ulcerative colitis (UC).
Read More
![](https://covid19.healthcare.pro/wp-content/uploads/2020/12/paris-1852928-1.jpg)
A clinical-stage biotechnology company announced the progression of its development program for its lead drug candidate, ABX464, into phase 3 preparation for the treatment of moderate-to-severe ulcerative colitis (UC).
Read More